Filing summary
Entera Bio Ltd. (Nasdaq: ENTX) filed this Form 8-K on October 6, 2026, reporting board changes. The filing does not report a financial-results period.
Board changes
- The board appointed Laura Hamill as a Class I director, effective December 1, 2026. She will serve until the 2027 Annual Meeting of Shareholders and until her successor is elected and qualified, unless her service ends earlier.
- Effective December 1, Ms. Hamill will also serve on the audit committee and the corporate governance and nomination committee. The board determined that she is independent under SEC and Nasdaq rules.
- Mr. Hamill will participate in the company’s standard non-employee director compensation arrangements, including annual cash payments and equity grants under the 2018 Equity Incentive Plan.
- Yonatan Malca notified the board that he will step down as a director effective December 1. The filing states his departure was not due to disagreement with the company.
Ms. Hamill has more than 35 years of biopharmaceutical commercial leadership experience, including senior roles at Gilead Sciences and Amgen, and serves on other public-company boards.
Financial performance and outlook
This filing provides no revenue, profit, cash flow, margin, debt, liquidity, guidance, or financial outlook figures. It also discloses no financial contingencies or unusual financial items.
Investor items to verify
- Confirm the appointments and committee assignments take effect on December 1, 2026.
- Review the company’s director compensation arrangements and any subsequent filings for additional details.
- Consult the company’s financial filings for current operating results, liquidity, and outlook; this 8-K does not provide those metrics.